home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

51.53 +0.02 (+0.04%)

Official Closing Price Updated: 4:10 PM EDT, Aug 4, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2

...

23 24 25 26 27 28 29 30 31

...

45 46 Next >

CureVac Shares Pop After Encouraging Update From COVID-19, Flu mRNA Vaccine Programs ↗

January 30, 2023

Via Benzinga

The RSV Vaccine Battle Wages On With Moderna Scoring A Win Vs. Pfizer, GSK ↗

January 30, 2023

But Moderna stock didn't move higher on the announcement.

Via Investor's Business Daily

How Could GSK's RSV Vaccine Change its Valuation?

January 26, 2023

GSK's RSV vaccine could be a good earner for the company, according to outside analysts and its own predictions for the future.

Via MarketBeat

Earnings Preview: GSK Q4 Earnings Expected To Decline ↗

January 25, 2023

This drug developer is expected to post quarterly earnings of $0.59 per share in its upcoming report, which represents a year-over-year change of -31.4%.

Via Talk Markets

3 Penny Stocks That Could Make You Filthy Rich ↗

January 25, 2023

These low-priced equities could deliver enormous returns for risk-tolerant shareholders.

Via The Motley Fool

Sandoz Acquires Antifungal Agent From Astellas, Reinforcing Hospital Offering ↗

January 24, 2023

Via Benzinga

GSK Earnings Conference Call Is Coming Up, Here's What You Need To Know ↗

January 23, 2023

Via Benzinga

COVID, Shmovid: This Could Be the Next Big Growth Story for Moderna Stock ↗

January 21, 2023

Moderna could follow closely behind Pfizer and GSK in entering the lucrative RSV vaccine market.

Via The Motley Fool

Stock Market Rally Pulls Back; Microsoft, Google Slash Jobs; Netflix, Goldman, Tesla In Focus: Weekly Review ↗

January 20, 2023

Microsoft and Google are slashing jobs. Netflix and Tesla jumped.

Via Investor's Business Daily

Pharmaceutical Stocks Pfizer, GSK, Moderna Come Close To Cracking A Multibillion-Dollar RSV Vaccine Market ↗

January 19, 2023

After years of lab failures, the companies could crack open a multibillion-dollar market.

Via Investor's Business Daily

Jim Cramer Says This Stock Up 23% In A Month Is 'A Great Speculative Buy' ↗

January 18, 2023

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Biohaven Ltd (NYSE: BHVN) is a "great speculative buy."

Via Benzinga

Moderna Gets A 'Booster' Shot: Why Stock Is Up Nearly 7% Today ↗

January 18, 2023

Moderna, Inc. (NASDAQ: MRNA) shares were solidly higher in premarket trading on Wednesday.

Via Benzinga

Moderna Comes Swinging For Pfizer, GSK As RSV Vaccine Battle Heats Up ↗

January 17, 2023

Moderna is stepping up to Pfizer and GSK, both of which are developing RSV vaccines.

Via Investor's Business Daily

Week In Review: WuXi Biologics Out-Licenses Four TCE Antibodies To GSK In $1.5 Billion Pact ↗

January 07, 2023

WuXi Biologics out-licensed global rights for up to four pre-clinical bi- & multi-specific TCE antibodies to GSK in a $1.5 billion agreement. WuXi Biologics will receive $40 million upfront and up to...

Via Talk Markets

CureVac (CVAC) Stock Rises 25% on Positive Data for Covid-19 and Flu Vaccines ↗

January 06, 2023

CureVac announced positive results for its mRNA-based Covid-19 and flu vaccine, which may offer tremendous relevance for CVAC stock.

Via InvestorPlace

The Year of the Tripledemic

January 03, 2023

COVID-19 may have lost its daily news headline status, but the disease rages on with 2700 weekly deaths in the U.S. and millions of Americans chronically disabled from long-COVID, 4 million of which...

Via TheNewswire.com

Topics Death

The Year of the Tripledemic

January 03, 2023

The Year of the Tripledemic

Via News Direct

Topics Death

What You Missed On Wall Street On Friday ↗

December 31, 2022

In the midst of markets falling, some companies had good news, while others took a hit from analysts and a merger is still on hold.

Via Talk Markets

GSK Looking For Under-Appreciated M&A Targets, Not Trying To Be Next Roche Or AstraZeneca ↗

December 30, 2022

GSK plc (NYSE: GSK) chief commercial officer Luke Miels says the company is looking at M&A targets that are under-appreciated worth $1 billion-$2.5 billion and avoid getting into a 'bidding war.'

Via Benzinga

Big Health Care Stocks to Watch in the New Year

December 29, 2022

Here are three health care stocks to watch as the New Year begins. Two have a moderate Buy rating while one is a Hold, for now.

Via MarketBeat

7 Drug Stocks That Will Soar in 2023 ↗

December 22, 2022

These drug stocks to buy look poised to generate huge profits for investors in 2023 and in subsequent years.

Via InvestorPlace

2 Smartest Tech Stocks to Buy in 2022 and Beyond ↗

December 20, 2022

The tech space is still bursting with opportunities for long-term investors.

Via The Motley Fool

Comparing With Pfizer's Vaccine, Icosavax RSV Candidate 'Could Establish Differentiation,' Analyst Says ↗

December 14, 2022

Via Benzinga

Options Trader Betting On GSK Stock Rising Heading Into 2023 ↗

December 13, 2022

Options traders are making big bets on the upside for healthcare, particularly in shares of GSK plc (NYSE: GSK).

Via Benzinga

Wave Life Sciences Shares Move Higher On Therapeutic Pact With GSK Targeting Genetic Disorders ↗

December 13, 2022

Via Benzinga

Wave Life Sciences and GSK Announce Collaboration to Drive Discovery and Development of Oligonucleotide Therapeutics Focusing on Novel Genetic Targets

December 13, 2022

From Wave Life Sciences USA, Inc.

Via GlobeNewswire

New data at ASH underscore the potential for durable, clinically important responses with momelotinib for myelofibrosis patients

December 11, 2022

From GSK plc

Via Business Wire

Can Pfizer, Johnson & Johnson Continue Outperforming the Index?

December 09, 2022

Large-cap pharmaceuticals Pfizer and Johnson & Johnson are outperforming the broader market in the past year, particularly in the past three months.

Via MarketBeat

France Health Body Advises Unfavorable Opinion Regarding Valneva's COVID-19 Vaccine ↗

December 08, 2022

Via Benzinga

GSK's Jemperli/Chemo Combo Shows Response Rate Of 46% In Head-To-Head Lung Cancer Trial ↗

December 07, 2022

Via Benzinga

< Previous 1 2

...

23 24 25 26 27 28 29 30 31

...

45 46 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com